Sodium glucose cotransporter 2 and the diabetic kidney

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 1, 2013, Pages 113-119

  Komala, Muralikrishna Gangadharan ^a   Panchapakesan, Usha ^a   Pollock, Carol ^a   Mather, Amanda ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

diabetic nephropathy; proximal tubule; sodium glucose cotransporter 2

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DAPAGLIFLOZIN; EMPAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER 2; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 6; IPRAGLIFLOZIN; LOSARTAN; LUSEOGLIFLOZIN; LX 4211; PHLORIZIN; PLACEBO; PROTEIN KINASE C; SERGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TOFGLIFLOZIN; TOLL LIKE RECEPTOR 2; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URIC ACID;

ADD ON THERAPY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GENE MUTATION; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; GLUCOSE TRANSPORT; GLUCOSURIA; GLYCEMIC CONTROL; INSULIN TREATMENT; KIDNEY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; REVIEW; SODIUM ABSORPTION; SODIUM TRANSPORT; URIC ACID BLOOD LEVEL;

ANIMALS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84871804484     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835a17ae     Document Type: Review

References (52)

1. Pyram R, Kansara A, Banerji MA, Loney-Hutchinson L. Chronic kidney disease and diabetes. Maturitas 2012; 71:94-103.
2. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012; 14:539-545.
3. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33:2217-2224.
4. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261:32-43.
5. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with noninsulin-dependent diabetes. Diabetes 2005; 54:3427-3434.
6. Gorboulev V, Schurmann A, Vallon V, et al. Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012; 61:187-196.
7. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22:104-112.
8. Kothinti RK, Blodgett AB, North PE, et al. A novel SGLT is expressed in the human kidney. Eur J Pharmacol 2012; 690:77-83.
9. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012; 14:5-14.
10. Tabatabai NM, Sharma M, Blumenthal SS, Petering DH. Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res Clin Pract 2009; 83:e27-e30.
11. Mather A, Pollock C. Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol 2010; 6:307-311.
12. Mather AJ PK, Mudaliar H, Pollock CA, Panchapakesan U. Renoprotection with sodium glucose cotransporter 2 inhibition [abstract]. In: ASN Kidney Week, November 2011. Philadelphia: ASN; 2011.
13. Maldonado-Cervantes MI, Galicia OG, Moreno-Jaime B, et al. Autocrine modulation of glucose transporter SGLT2 by IL-6 and TNF-alpha in LLCPK( 1) cells. J Physiol Biochem 2012; 68:411-420.
14. Beloto-Silva O, Machado UF, Oliveira-Souza M. Glucose-induced regulation of NHEs activity and SGLTs expression involves the PKA signaling pathway. J Membr Biol 2011; 239:157-165.
15. Ghezzi C, Wright EM. Regulation of the human Na+-dependent glucose cotransporter hSGLT2. Am J Physiol Cell Physiol 2012; 303:C348-C354.
16. Osorio H, Bautista R, Rios A, et al. Effect of treatment with losartan on salt sensitivity and SGLT2 expression in hypertensive diabetic rats. Diabetes Res Clin Pract 2009; 86:e46-e49.
17. Marks J, Carvou NJ, Debnam ES, et al. Diabetes increases facilitative glucose uptake and GLUT2 expression at the rat proximal tubule brush border membrane. J Physiol 2003; 553:137-145.
18. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92:158-169.
19. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999; 56:1627-1637.
20. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
21. Tang SC, Lai KN. The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant 2012; 27:3049-3056.
22. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010; 21:212-222.
23. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19:433-442.
24. Pollock CA, Lawrence JR, Field MJ. Tubular sodium handling and tubuloglomerular feedback in experimental diabetes mellitus. Am J Physiol 1991; 260:F946-F952.
25. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in prediabetes and prehypertension. Nephrol Dial Transplant 2012; 27:1708-1714.
26. Takenaka T, Inoue T, Ohno Y, et al. Elucidating mechanisms underlying altered renal autoregulation in diabetes. Am J Physiol Regul Integr Comp Physiol 2012; 305:R495-R504.
27. Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302:R75-R83.
28. Magen D, Sprecher E, Zelikovic I, Skorecki K. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria. Kidney Int 2005; 67:34-41.
29. Calado J, Loeffler J, Sakallioglu O, et al. Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Kidney Int 2006; 69:852-855.
30. Lee H, Han KH, Park HW, et al. Familial renal glucosuria: a clinicogenetic study of 23 additional cases. Pediatr Nephrol 2012; 27:1091-1095.
31. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14:2873-2882.
32. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002; 111:544-547.
33. Ly JP, Onay T, Sison K, et al. The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol 2011; 22:113-123.
34. Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics 2011; 12:1119-1126.
35. Wilding JP, Norwood P, T'Joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes care 2009; 32:1656-1662.
36. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:2223-2233.
37. Gross JL, Schernthaner G, Fu M, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract]. In: Abstracts of the 72nd Scientific sessions of The American Diabetic Association; 8-12 June 2012; Philadelphia; 2012.
38. Patel A, MacMahon S, Chalmers J, Neal B, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358:2560-2572.
39. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48:1794-1800.
40. Adachi T, Yasuda K, Okamoto Y, et al. T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabol Clin Exp 2000; 49:990-995.
41. Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001; 132:578-586.
42. Dapagliflozin EMDAC Background Document. Public Access Document; FDA. 2011.
43. Donald E. Kohan PF, List J, Tang W. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract]. In: ASN Kidney Week 2011. Philadelphia: ASN; 2011.
44. Yale JF, Bakris G, Xi L et al. Canagliflozin (CANA), a sodium glucose cotransporter 2 (SGLT2) inhibitor, improves glycemia and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment [abstract]. In: Abstracts of the 72nd Scientific Sessions of The American Diabetic Association. Philadelphia; 8-12 June, 2012.
45. Woerle H, Ferraninni E, Berk A et al. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes [abstract]. In: Abstracts of the 72nd Scientific Sessions of The American Diabetic Association. Philadelphia; 2012.
46. Jurczak MJ, Lee HY, Birkenfeld AL, et al. SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 2011; 60:890-898.
47. Osorio H, Bautista R, Rios A, et al. Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J Nephrol 2010; 23:541-546.
48. NauckMA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34:2015-2022.
49. Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs 2010; 19:1581-1589.
50. Doblado M, Moley KH. Facilitative glucose transporter 9, a unique hexose and urate transporter. Am J Physiol Endocrinol Metabol 2009; 297:E831-E835.
51. Cain L, Shankar A, Ducatman AM, Steenland K. The relationship between serum uric acid and chronic kidney disease among Appalachian adults. Nephrol Dial Transplant 2010; 25:3593-3599.
52. Hummel CS, Lu C, Liu J, et al. Structural selectivity of human SGLT inhibitors. Am J Physiol Cell Physiol 2012; 302:C373-C382.